Novel Arylimidamides for Treatment of Visceral Leishmaniasis䌤† Michael Zhuo Wang,1* Xiaohua Zhu,2 Anuradha Srivastava,3 Qiang Liu,4 J. Mark Sweat,3 Trupti Pandharkar,2 Chad E. Stephens,5 Ed Riccio,6 Toufan Parman,6 Manoj Munde,7 Swati Mandal,8 Rentala Madhubala,8 Richard R. Tidwell,1,4 W. David Wilson,7 David W. Boykin,7 James Edwin Hall,4 Dennis E. Kyle,3 and Karl A. Werbovetz2
Received 19 February 2010/Returned for modification 1 March 2010/Accepted 29 March 2010
Arylimidamides (AIAs) represent a new class of molecules that exhibit potent antileishmanial activity (50% inhibitory concentration [IC50],
